- Home
- CYTK
as 04-14-2025 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 5.6B | IPO Year: | 2004 |
| Target Price: | $82.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $32.74 - $71.60 | Next Earning Date: | 05-07-2025 |
| Revenue: | $18,474,000 | Revenue Growth: | 145.34% |
| Revenue Growth (this year): | 55.84% | Revenue Growth (next year): | 659.85% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | Apr 8 '25 | Sell | $36.18 | 2,000 | $72,360.00 | 140,255 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Apr 7 '25 | Sell | $35.78 | 2,886 | $103,261.08 | 64,689 | |
| Harrington Robert Arthur | CYTK | Director | Apr 3 '25 | Sell | $39.43 | 450 | $17,743.50 | 14,658 | |
| Blum Robert I | CYTK | President & CEO | Mar 31 '25 | Sell | $40.75 | 15,000 | $611,250.00 | 427,629 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Mar 18 '25 | Sell | $43.58 | 2,000 | $87,160.00 | 140,255 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Mar 17 '25 | Sell | $44.38 | 4,389 | $194,783.82 | 140,255 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 17 '25 | Sell | $44.76 | 23,675 | $1,066,580.50 | 64,689 | |
| Blum Robert I | CYTK | President & CEO | Mar 17 '25 | Sell | $44.52 | 37,648 | $1,677,568.24 | 427,629 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 14 '25 | Sell | $45.00 | 100 | $4,500.00 | 64,689 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Mar 13 '25 | Sell | $43.62 | 26,771 | $1,167,751.02 | 64,689 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
The Wall Street Journal
4 days ago
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Argus Research
7 days ago
CYTK: Lowering target price to $28.00
Zacks
8 days ago
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Investor's Business Daily
13 days ago
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Investopedia
13 days ago
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
Argus Research
14 days ago
CYTK: Lowering target price to $30.00
MT Newswires
15 days ago
Cytokinetics Insider Sold Shares Worth $611,250, According to a Recent SEC Filing
GlobeNewswire
15 days ago
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.